Table 1.
The mean body mass index of LADA.
| Study | Country | Type of study | Number of sample size | Age range, yr | Ab | Mean BMI (kg/m2) |
|---|---|---|---|---|---|---|
| Tianjin (2005) | China (Tianjin) |
Population based | 8,109 | ≥15 | GAD | 25.7 ± 3.4 |
| Lee et al. (17) | Korea | Clinical based | 1,370 | 47–62 | GAD and/or IA-2 | 23.1 ± 3.7 |
| LADA China (2013) | China | Multicenter, clinical based | 5,324 | ≥20 | GAD | 23.9 ± 3.7 |
| UKPDS 25 (1997) | United Kingdom | Clinical based | 3,672 | 25–65 | GAD and/or ICA | 29.5 ± 5.5 |
| ADOPT (2004) | USA, Europe | Multicenter, clinical based | 4,357 | 30–75 | GAD and/or IA-2 | 31.4 ± 0.466 |
| NIRAD (2007) | Italy | Multicenter, clinical based | 4,250 | 30–75 | GAD and/or IA-2 | 27 ± 5.16 |
| Action LADA (2009) | Europe | Multicenter, clinical based | 6,810 | 30–70 | GAD and/or IA-2, ZnT8 | 27.2 ± 6.2 |
| Maioli et al. (23) | Italy (Sardinia) | Clinical based | 5,568 | 35–70 | GAD | 27.7 ± 4.8 |
| Hawa et al. (24) | Europe | Multicenter, clinical based | 2,838 | 40–75 | GAD and/or IA-2, ZnT8 | 27.3 ± 3.6 |
| Maddaloni et al. (25) | United Arab Emirates | Clinical based | 17,072 | 30–70 | GAD and/or IA-2 | 30.7 ± 6.2 |
| Lofvenborg et al. (26) | Swedish | Population based | 2,125 | ≥35 | GAD | 27.7 ± 5.2 |
LADA, latent autoimmune diabetes in adults; GAD, glutamic acid decarboxylase; ICA, islet cell; IA-2, protein tyrosine phosphatase; ZnT8, islet-specific zinc transporter isoform 8.